Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Astellas Pharma Inc
YPHAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan. Address: 2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411
Analytics
Zielpreis von Wall Street
–KGV
128.625Dividendenrendite
4.41 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen YPH
Dividenden-Analyse YPH
Dividendenwachstum über 5 Jahre
76 %Kontinuierliches Wachstum
10 JahreAusschüttungsquote 5-Jahres-Durchschnitt
66 %Verlauf der Dividende YPH
Bewertung der Aktie YPH
Finanzen YPH
Ergebnisse | 2019 | Dynamik |